Comparing chemotherapy and surgery for rectal cancer after local resection
Official title: A Prospective, Multicenter, Randomized, Open, Parallel Controlled, Non-inferiority Clinical Trial of Salvage Chemoradiotherapy Versus Radical Total Mesorectal Excision in the Treatment of Intermediate-risk Early Middle-low Rectal Cancer After Local Resection
Run by Sun Yat-sen University · NCT06043999 · Data updated 2026-11-12
This study is testing whether chemotherapy or surgery works better for people with intermediate-risk rectal cancer who have already had part of their tumor removed.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 392 (estimated) |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | September 1, 2023 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | September 21, 2023 |
| Trial ID | NCT06043999 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-75 with specific characteristics of T1 rectal adenocarcinoma who have undergone local radical resection.
✕Probably not a fit
Patients with other malignant tumors, inflammatory bowel disease, or those unsuitable for chemotherapy or surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates whether salvage chemotherapy or total mesorectal excision (TME) is more effective for patients with intermediate-risk T1 rectal cancer who have undergone local resection. It aims to address the controversy surrounding the best treatment approach by comparing outcomes such as overall survival and disease-free survival between the two interventions. The study will include patients aged 18-75 who meet specific criteria related to tumor characteristics and health status. The goal is to determine the optimal treatment strategy that minimizes complications while effectively managing cancer recurrence.
Why it matters
Potential benefit: If successful, this study could provide a less invasive treatment option for rectal cancer patients, potentially improving their quality of life and reducing surgical complications.
How similar studies have gone: Previous studies have shown no significant difference in survival outcomes between salvage chemotherapy and TME, indicating that this approach is based on existing evidence but may still be novel in its specific application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. aged 18-75 years; 2. Local radical resection of rectal adenocarcinoma (TEM, TAMIS, TSPM, EMR, ESD or polypectomy) 3. pT1 with a diameter of 3-5 cm, or a maximum diameter of 3 cm, and at least poor differentiation and/or lymphovascular invasion and/or perineural invasion and/or SM3; 4. The distance from the lower edge of the tumor to the anal verge was within 10cm on MRI at initial diagnosis; 5. clinical stage N0M0 at initial diagnosis; 6. no multiple colorectal cancer; 7. The heart, lung, liver and kidney function can tolerate surgery; 8. Patients and their families were able to understand and willing to participate in this study, and provided written informed consent Exclusion Criteria: 1. complicated with other malignant tumors or a previous history of malignant tumors; 2. not suitable for subsequent chemoradiotherapy or surgery; 3. a history of inflammatory bowl disease (IBD) or familial adenomatous polyposis (FAP); 4. recently diagnosed with other malignant tumors; 5. ASA physical status ≥ IV and/or ECOG performance status \> 2 points; 6. patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or combined with serious underlying diseases can not tolerate surgery; 7. a history of severe mental illness; 8. pregnant or lactating women; 9. Patients with other clinical or laboratory conditions were not considered to be eligible for the study
Where it's running
-
Gastrointestinal Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Liang Huang, phD
- Email: huangl75@mail.sysu.edu.cn
- Phone: 15989101216
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing drug sensitivity in micro tumors to guide treatment for colorectal cancer
This study is testing whether a new 3D drug sensitivity test on tiny tumors can help guide better treatment decisions for people with colorectal cancer after surgery.
-
Single vs. double stapling and purse-string techniques after rectal cancer surgery
This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
Rectal cancer registry to track real-world treatments and outcomes
This registry collects real-world data on how locally advanced rectal cancer is treated in Austria, to see how TNT and dMMR/MSI-H cases are managed and what outcomes occur.
-
Aerobic exercise and guided imagery for bowel problems after rectal cancer surgery
This study tests whether a program of aerobic exercise plus guided imagery helps people with low anterior resection syndrome after rectal cancer surgery.
-
Active surveillance vs chemoradiotherapy after local removal of intermediate-risk T1 rectal cancer
This study tests whether close follow-up alone after local removal of early rectal cancer can match the cancer control of adding chemoradiotherapy, while reducing treatment-related side effects.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.